086060 — Genebiotech Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro CapNeutral

Annual cashflow statement for Genebiotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-484	1,523	2,591	2,865	3,789
Depreciation
Amortisation
Non-Cash Items	452	135	1,459	857	713
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-4,053	-6,624	1,980	-5,554	1,726
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-2,841	-3,679	7,369	-464	7,614
Capital Expenditures	-3,115	-1,174	-767	-1,183	-3,760
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	9,025	1,824	-4,559	153	-3,553
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	5,910	650	-5,326	-1,030	-7,312
Financing Cash Flow Items	-3,247	—	—	—	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-4,490	3,035	-713	2,976	-993
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1,364	-0.077	1,321	1,529	-692